0001209191-22-054667.txt : 20221026
0001209191-22-054667.hdr.sgml : 20221026
20221026180619
ACCESSION NUMBER: 0001209191-22-054667
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221024
FILED AS OF DATE: 20221026
DATE AS OF CHANGE: 20221026
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: JANKOWSKI JESS
CENTRAL INDEX KEY: 0001184478
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22333
FILM NUMBER: 221334290
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NANOPHASE TECHNOLOGIES Corp
CENTRAL INDEX KEY: 0000883107
STANDARD INDUSTRIAL CLASSIFICATION: MISCELLANEOUS PRIMARY METAL PRODUCTS [3390]
IRS NUMBER: 363687863
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1319 MARQUETTE DRIVE
CITY: ROMEOVILLE
STATE: IL
ZIP: 60446
BUSINESS PHONE: 6303231200
MAIL ADDRESS:
STREET 1: 1319 MARQUETTE DRIVE
CITY: ROMEOVILLE
STATE: IL
ZIP: 60446
FORMER COMPANY:
FORMER CONFORMED NAME: NANOPHASE TECHNOLOGIES CORPORATION
DATE OF NAME CHANGE: 19970305
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-10-24
0
0000883107
NANOPHASE TECHNOLOGIES Corp
NANX
0001184478
JANKOWSKI JESS
1319 MARQUETTE DRIVE
ROMEOVILLE
IL
60446
1
1
0
0
President, CEO
Common Stock
1000
I
Spouse's IRA
Common Stock
59000
D
Common Stock
2022-10-24
4
M
0
2500
0.415
A
61500
D
Common Stock
2022-10-24
4
S
0
2500
2.35
D
59000
D
Common Stock
2022-10-25
4
M
0
800
0.415
A
59800
D
Common Stock
2022-10-25
4
S
0
800
2.34
D
59000
D
Common Stock (right to purchase)
0.415
2022-10-24
4
M
0
2500
0.415
D
2014-02-14
2023-02-14
Common Stock
90000
87500
D
Common Stock (right to purchase)
0.415
2022-10-25
4
M
0
800
0.415
D
2014-02-14
2023-02-14
Common Stock
87500
86700
D
Common Stock (right to purchase)
0.52
2015-02-13
2024-02-13
Common Stock
90000
90000
D
Common Stock (right to purchase)
0.44
2016-02-18
2025-02-18
Common Stock
81000
81000
D
Common Stock (right to purchase)
0.42
2017-02-23
2026-02-23
Common Stock
69000
69000
D
Common Stock (right to purchase)
0.68
2018-02-21
2027-02-21
Common Stock
81000
81000
D
Common Stock (right to purchase)
0.82
2019-05-23
2028-05-23
Common Stock
90000
90000
D
Common Stock (right to purchase)
0.51
2020-05-22
2029-05-22
Common Stock
16500
16500
D
Common Stock (right to purchase)
0.45
2021-06-18
2027-06-18
Common Stock
90000
90000
D
Common Stock (right to purchase)
4.17
2022-12-28
2028-12-28
Common Stock
90000
90000
D
These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors.
These stock options are set to expire on 02/14/2023. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker. His goal is to have this broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors.
Subject to certain restrictions, beginning on this date, options vest in three equal installments.
Subject to certain restrictions, beginning on this date, the options vest in three equal annual installments.
Subject to certain restrictions, beginning on this date, options vest in three equal annual installments.
Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having shares from this grant sold, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. The maturity of these rights cannot be extended beyond the IRS statutory limit of ten years.
Jess A. Jankowski
2022-10-26